ANN ARBOR – Blaze Medical Devices, a startup medical device company, has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 New York, NY.
The Forum helps family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
?With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,? said Michael Moffat, Cavendish co-founder and President.
?The quality and originality of Blaze?s research and scientific insights in the field of blood analysis, particularly measuring red blood cell (RBC) damage, positions them to make a major contribution to the hemocompatibility testing of blood-handling medical devices like dialysis machines and blood-affecting drugs for safer performance, as well as quality testing of stored blood for improving its utilization and inventory management which could improve transfusion efficacy and safety, conserve blood, and reduce healthcare costs.?
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences.
About Blaze Medical Devices
